(USD) | Sep 2023 | Q/Q |
---|---|---|
Revenue | 50K | - |
Gross Profit | - | - |
Cost Of Revenue | - | - |
Operating Income | -5.1MM | +3% |
Operating Expenses | 5.2MM | +4% |
Net Income | - | - |
R&D | 1.6MM | -32% |
G&A | 3.5MM | +36% |
Amortization | 5K | - |
Interest Expense | 26K | +53% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
The healthcare industry has historically provided significant returns to investors, with a predicted CAGR of 12.71% until 2027. Although many successful and profitable companies experience a surge in stock price, the healthcare industry also has many stocks that plummet. This is because many healthcare companies rely on trials that need to be approved by the Food and Drug Administration (FDA), making their performance difficult to predict. Many companies, particularly small-cap companies, see ma
– Leading AI and precision biologics innovators to build a diverse set of novel best-in-class obesity treatments – – iBio to use its patented generative AI/Machine Learning platform to discover, engineer and develop obesity-focused therapeutic targets – – Concurrent $15M PIPE financing, announced yesterday, extends cash runway through fiscal year 2025 and provides support for collaboration – – Company to host webcasted conference call today at 8:30 a.m. EDT to discuss AstralBio collaboration – B
– Purchase price of $2.85 represents a premium of 148+% to last close – BRYAN, Texas and SAN DIEGO, March 26, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announces today that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds to the Company of approximately $15.0 million, before deducting placement
In this article, we discuss the 12 best biotech penny stocks to invest in. If you want to skip our detailed analysis of these stocks, go directly to 5 Best Biotech Penny Stocks to Invest In. The past few years have been a topsy-turvy ride for the biotech sector. There was a massive increase in […]
– Deal includes $1 million upfront and potential future milestone payments – – iBio’s proprietary therapeutic pipeline will now be comprised entirely of promising immuno-oncology candidates – BRYAN, Texas and SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announces today that it has entered into an asset purchase agreement (“Agreement”) with Otsuka Pharmaceutical Co., Ltd. (“Otsuka”), p
- VP of Platform Technologies, Matt Greving, to give podium presentation on enhancing bispecific T-cell engager discovery and development with machine learning -BRYAN, Texas and SAN DIEGO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today that Matthew P. Greving Ph.D., its Vice President and Head of Platform Technologies and Machine Learning, will give a podium presentation titled "En
– Extends maturity date to March 29, 2024 – – Allows for more time to complete planned divestiture of legacy CDMO business - BRYAN, Texas and SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced its wholly owned subsidiary, iBio CDMO LLC, and its lender, Woodforest National Bank (“Woodforest”), have entered into an amendment (the “Amendment”) to the Credit Agreement dated Nove
BRYAN, Texas and SAN DIEGO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), today announced the pricing of its reasonable best efforts public offering of 2,250,000 of its shares of common stock (or common stock equivalents in lieu thereof) and accompanying Series C and Series D warrants to purchase up to an aggregate of 2,250,000 shares of common stock at a combined public offering price of $2.00, resulting in gross proceeds of approximately $4.5 million. The
BRYAN, Texas and SAN DIEGO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) today announced that its Board of Directors has approved a 20-to-1 reverse split of the Company’s common stock, par value $0.001 per share (the “Common Stock”) effective at 12:01 a.m. ET on November 29, 2023 (the “Effective Date”). The Common Stock is expected to begin trading on a split-adjusted basis when the market opens on November 29, 2023, with the new CUSIP number 451033708. The
- ShieldTx potentially increases safety and developability of therapeutic antibodies for difficult targets and modes of action - BRYAN, Texas and SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) today announced the expansion of its AI-powered technology stack with the launch of ShieldTx, a patent-pending antibody masking technology designed to enable specific, highly targeted antibody delivery to diseased tissue without harming healthy tissue. By add